Briacell Change To Account Receivables vs Begin Period Cash Flow Analysis

Stocks . USA . 
Stock . Briacell Therapeutics Corp
BCTX Stock  USD 0.53  0.03  5.54%   
Briacell Therapeutics financial indicator trend analysis is way more than just evaluating Briacell Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Briacell Therapeutics is a good investment. Please check the relationship between Briacell Therapeutics Change To Account Receivables and its Begin Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Briacell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Change To Account Receivables vs Begin Period Cash Flow

Change To Account Receivables vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Briacell Therapeutics Change To Account Receivables account and Begin Period Cash Flow. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Briacell Therapeutics' Change To Account Receivables and Begin Period Cash Flow is -0.28. Overlapping area represents the amount of variation of Change To Account Receivables that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Briacell Therapeutics Corp, assuming nothing else is changed. The correlation between historical values of Briacell Therapeutics' Change To Account Receivables and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Account Receivables of Briacell Therapeutics Corp are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Change To Account Receivables i.e., Briacell Therapeutics' Change To Account Receivables and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.28
Relationship DirectionNegative 
Relationship StrengthInsignificant

Change To Account Receivables

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most indicators from Briacell Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Briacell Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Briacell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
At this time, Briacell Therapeutics' Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 77 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 4.2 M in 2024.

Briacell Therapeutics fundamental ratios Correlations

Total Assets
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Shares Outstanding
Non Current Liabilities Total
Other Stockholder Equity
Total Liab
Total Current Assets
Net Receivables
Other Current Liab
Property Plant And Equipment Net
Inventory
Other Current Assets
Property Plant And Equipment Gross
Short Term Investments
Intangible Assets
Net Tangible Assets
Current Deferred Revenue
Net Invested Capital
Total Assets
-0.10.79-0.98-0.33-0.050.98-0.04-0.10.980.450.540.720.520.980.02-0.08-0.050.090.35-0.05-0.450.420.84-0.440.79
Total Current Liabilities
-0.1-0.290.17-0.750.92-0.18-0.080.93-0.190.68-0.07-0.020.12-0.140.90.19-0.23-0.930.22-0.23-0.510.410.06-0.53-0.24
Total Stockholder Equity
0.79-0.29-0.80.18-0.220.80.09-0.210.8-0.07-0.060.91-0.10.77-0.26-0.140.110.22-0.140.11-0.160.170.89-0.130.98
Net Debt
-0.980.17-0.80.240.15-1.00.190.19-1.0-0.37-0.52-0.69-0.49-1.00.090.030.18-0.18-0.30.180.41-0.43-0.840.42-0.83
Retained Earnings
-0.33-0.750.180.24-0.76-0.240.13-0.7-0.23-0.98-0.56-0.03-0.7-0.3-0.860.010.260.72-0.670.260.62-0.52-0.230.650.13
Accounts Payable
-0.050.92-0.220.15-0.76-0.160.050.99-0.160.72-0.070.050.1-0.110.96-0.19-0.1-0.990.18-0.09-0.360.210.13-0.36-0.19
Cash
0.98-0.180.8-1.0-0.24-0.16-0.19-0.191.00.360.520.690.491.0-0.1-0.03-0.180.180.3-0.18-0.40.440.84-0.430.83
Non Current Assets Total
-0.04-0.080.090.190.130.05-0.190.04-0.19-0.13-0.170.2-0.19-0.20.01-0.240.98-0.03-0.20.990.09-0.33-0.130.32-0.12
Non Currrent Assets Other
-0.10.93-0.210.19-0.70.99-0.190.04-0.20.66-0.150.030.02-0.160.93-0.18-0.11-0.990.09-0.11-0.310.240.12-0.38-0.18
Cash And Short Term Investments
0.98-0.190.8-1.0-0.23-0.161.0-0.19-0.20.350.520.690.491.0-0.11-0.04-0.180.190.29-0.18-0.390.430.84-0.420.83
Common Stock Shares Outstanding
0.450.68-0.07-0.37-0.980.720.36-0.130.660.350.620.090.740.420.81-0.1-0.24-0.670.62-0.24-0.580.490.31-0.63-0.02
Non Current Liabilities Total
0.54-0.07-0.06-0.52-0.56-0.070.52-0.17-0.150.520.62-0.10.980.560.110.02-0.160.130.71-0.17-0.340.340.09-0.37-0.03
Other Stockholder Equity
0.72-0.020.91-0.69-0.030.050.690.20.030.690.09-0.1-0.090.680.03-0.080.18-0.050.080.18-0.370.150.89-0.160.87
Total Liab
0.520.12-0.1-0.49-0.70.10.49-0.190.020.490.740.98-0.090.540.270.08-0.22-0.040.76-0.22-0.450.420.1-0.48-0.07
Total Current Assets
0.98-0.140.77-1.0-0.3-0.111.0-0.2-0.161.00.420.560.680.54-0.04-0.03-0.190.150.37-0.19-0.430.450.84-0.450.8
Net Receivables
0.020.9-0.260.09-0.860.96-0.10.010.93-0.110.810.110.030.27-0.04-0.16-0.13-0.930.41-0.13-0.410.290.15-0.45-0.23
Other Current Liab
-0.080.19-0.140.030.01-0.19-0.03-0.24-0.18-0.04-0.10.02-0.080.08-0.03-0.16-0.230.140.13-0.23-0.490.28-0.17-0.27-0.11
Property Plant And Equipment Net
-0.05-0.230.110.180.26-0.1-0.180.98-0.11-0.18-0.24-0.160.18-0.22-0.19-0.13-0.230.13-0.231.00.17-0.41-0.160.41-0.1
Inventory
0.09-0.930.22-0.180.72-0.990.18-0.03-0.990.19-0.670.13-0.05-0.040.15-0.930.140.13-0.130.120.36-0.22-0.120.360.19
Other Current Assets
0.350.22-0.14-0.3-0.670.180.3-0.20.090.290.620.710.080.760.370.410.13-0.23-0.13-0.23-0.490.280.15-0.35-0.1
Property Plant And Equipment Gross
-0.05-0.230.110.180.26-0.09-0.180.99-0.11-0.18-0.24-0.170.18-0.22-0.19-0.13-0.231.00.12-0.230.17-0.41-0.160.41-0.1
Short Term Investments
-0.45-0.51-0.160.410.62-0.36-0.40.09-0.31-0.39-0.58-0.34-0.37-0.45-0.43-0.41-0.490.170.36-0.490.17-0.52-0.360.6-0.18
Intangible Assets
0.420.410.17-0.43-0.520.210.44-0.330.240.430.490.340.150.420.450.290.28-0.41-0.220.28-0.41-0.520.37-0.980.26
Net Tangible Assets
0.840.060.89-0.84-0.230.130.84-0.130.120.840.310.090.890.10.840.15-0.17-0.16-0.120.15-0.16-0.360.37-0.380.92
Current Deferred Revenue
-0.44-0.53-0.130.420.65-0.36-0.430.32-0.38-0.42-0.63-0.37-0.16-0.48-0.45-0.45-0.270.410.36-0.350.410.6-0.98-0.38-0.21
Net Invested Capital
0.79-0.240.98-0.830.13-0.190.83-0.12-0.180.83-0.02-0.030.87-0.070.8-0.23-0.11-0.10.19-0.1-0.1-0.180.260.92-0.21
Click cells to compare fundamentals

Briacell Therapeutics Account Relationship Matchups

High Positive Relationship

Cash And Short Term Investments
+ 1.0
Cash
Total Current Assets
+ 1.0
Cash
Total Current Assets
+ 1.0
Cash And Short Term Investments
Property Plant And Equipment Gross
+ 1.0
Property Plant And Equipment Net
Non Currrent Assets Other
+ 0.99
Accounts Payable
Property Plant And Equipment Gross
+ 0.99
Non Current Assets Total

High Negative Relationship

Total Current Assets
- 1.0
Net Debt
Cash And Short Term Investments
- 1.0
Net Debt
Cash
- 1.0
Net Debt
Inventory
- 0.99
Non Currrent Assets Other
Inventory
- 0.99
Accounts Payable
Current Deferred Revenue
- 0.98
Intangible Assets

Briacell Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets478.3K58.0M42.6M27.2M5.9M10.3M
Total Current Liabilities3.6M556.8K941.1K1.8M7.5M7.8M
Total Stockholder Equity(3.3M)57.3M10.3M(3.8M)(2.4M)(2.3M)
Net Debt209.3K(57.2M)(41.0M)(21.3M)(862.1K)(905.2K)
Retained Earnings(16.6M)(15.8M)(60.3M)(80.7M)(85.4M)(81.2M)
Accounts Payable4.2K214.1K463.3K1.1M7.2M7.5M
Cash19.5K57.3M41.0M21.3M862.1K819.0K
Non Current Assets Total238.9K245.6K230.3K215.1K2.2M1.2M
Cash And Short Term Investments19.5K57.3M41.0M21.3M862.1K819.0K
Common Stock Shares Outstanding713.9K4.5M15.5M15.6M16.5M17.3M
Liabilities And Stockholders Equity478.3K58.0M42.6M27.2M5.9M10.3M
Non Current Liabilities Total142.8K225.4K31.3M29.1M1.1M1.0M
Other Stockholder Equity2.2M39.0M5.2M7.4M11.0M8.1M
Total Liab3.8M782.2K32.2M30.9M8.6M4.8M
Total Current Assets239.4K57.8M42.3M26.9M3.7M3.5M
Net Receivables20.6K12.6K24.1K717.7K1.4M1.4M
Other Current Liab3.4M480.7K741.8K677.7K290.4K275.9K
Inventory(305.0)1.0(24.1K)(18.9K)(1.4M)(1.3M)
Other Current Assets199.7K516.9K1.3M5.0M1.4M721.5K
Accumulated Other Comprehensive Income(81.0K)(94.5K)(127.0K)(138.7K)(124.8K)(118.6K)
Intangible Assets238.9K245.6K230.3K215.1K199.8K182.9K
Net Tangible Assets(1.2M)(4.7M)57.0M10.1M11.6M11.5M
Net Invested Capital(4.1M)57.3M10.3M(3.8M)(2.4M)(2.3M)
Net Working Capital(4.5M)57.2M41.4M25.1M(3.8M)(3.6M)
Common Stock11.2M54.8M65.6M69.6M72.2M41.0M
Capital Stock11.2M54.8M65.6M69.6M72.2M45.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor

Additional Tools for Briacell Stock Analysis

When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY